• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NuVasive gains on narrower Q4 losses, revenue beat

NuVasive gains on narrower Q4 losses, revenue beat

February 27, 2013 By Brad Perriello

NuVasive

Shares of NuVasive Inc. (NSDQ:NUVA) closed up nearly 7% yesterday after the medical device company reported narrowing its 4th-quarter losses by some 73% and beat Wall Street’s sales expectations for the quarter.

The San Diego-based spinal implant maker posted losses of $2.7 million, or 6¢ per share, on sales of $165.8 million for the 3 months ended Dec. 31, 2012, for sales growth of 10.4%.

Adjusted to exclude 1-time items, earnings per share were 34¢, a full 13¢ above expectations on The Street, where analysts were also looking for revenues of $156.4 million.

NUVA shares closed up 6.7% at $18.42 yesterday on the news.

Chairman & CEO Alex Lukianov said NuVasive has largely recovered from alleged poaching of sales reps by rivals, telling analysts during a conference call that the company’s new sales hires "pedigree is just superb."

"The challenging spine environment has also driven some of our competitors to adopt unsustainable tactics to poach our sales representatives. Those tactics negatively impacted our results in the 3rd quarter. And in response, we acted quickly to implement solutions designed to rebuild sales momentum. The strength of our 4th-quarter results gives us confidence in our ability to execute that strategy," Lukianov said. "I was just looking at some of the recent hires and the pedigree is just superb, the last several months in particular. They’re coming from the major spine companies. So there is actually a very, very good stability. And there’s I think a very strong pipeline for us to add the additional representatives that we plan to do in 2013."

Lukianov said NuVasive expects little or no growth for the global spine market this year and flat to negative growth in the U.S. The company forecast 2013 revenues of about $655 million, or 6% growth. Earnings per share are pegged at about 7¢ apiece with adjusted EPS of roughly $1.

As for its ongoing patent infringement war with industry titan Medtronic (NYSE:MDT), Lukianov said the U.S. District Court for Southern California has yet to decide the royalty rates NuVasive owes to Medtronic. An appeal is on hold pending that decision, he said.

"So really not much has changed since we’ve been reporting on this the last few quarters. There was a judge change last year. And since that time, she has not ruled on the royalty rate, on whether it stays the same or goes down or whatever happens to it. So we’re still waiting to see when that will take place," Lukianov said. "It is holding back our ability to keep things moving with regard to the appeal. So we are eager to get it done."

Another legal imbroglio, a trademark infringement case against NeuroVision Medical Products, is expected to see a new trial in June, he said.

Filed Under: MassDevice Earnings Roundup, News Well, Spine Tagged With: 2012, Nuvasive, Q4

More recent news

  • GT Medical raises $53M to support brain tumor treatment
  • Imperative Care, Proximie partner to develop surgical robot to treat stroke
  • Carlsmed launches IPO roadshow
  • Varian introduces IntelliBlate for image-guided cancer therapy in Europe
  • Henry Schein CEO Stanley M. Bergman to retire

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy